97 related articles for article (PubMed ID: 15569635)
1. Ligand epitope antigen presentation system vaccines against herpes simplex virus.
Goel N; Zimmerman DH; Rosenthal KS
Front Biosci; 2005 Jan; 10():966-74. PubMed ID: 15569635
[TBL] [Abstract][Full Text] [Related]
2. The L.E.A.P.S. approach to vaccine development.
Zimmerman DH; Rosenthal KS
Front Biosci; 2005 Jan; 10():790-8. PubMed ID: 15569618
[TBL] [Abstract][Full Text] [Related]
3. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.
Taylor PR; Koski GK; Paustian CC; Bailey E; Cohen PA; Moore FB; Zimmerman DH; Rosenthal KS
Vaccine; 2010 Aug; 28(34):5533-42. PubMed ID: 20600501
[TBL] [Abstract][Full Text] [Related]
4. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.
Goel N; Rong Q; Zimmerman D; Rosenthal KS
Vaccine; 2003 Oct; 21(27-30):4410-20. PubMed ID: 14505924
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1.
Rosenthal KS; Mao H; Horne WI; Wright C; Zimmerman D
Vaccine; 1999 Feb; 17(6):535-42. PubMed ID: 10075159
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
11. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
[TBL] [Abstract][Full Text] [Related]
12. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens.
Taylor PR; Paustian CC; Koski GK; Zimmerman DH; Rosenthal KS
Cell Immunol; 2010; 262(1):1-5. PubMed ID: 20163792
[TBL] [Abstract][Full Text] [Related]
13. LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.
Zimmerman DH; Steiner H; Carmabula R; Talor E; Rosenthal KS
J Vaccines Vaccin; 2012 Sep; 3(5):. PubMed ID: 23400692
[TBL] [Abstract][Full Text] [Related]
14. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.
Liu K; Jiang D; Zhang L; Yao Z; Chen Z; Yu S; Wang X
Vaccine; 2012 Apr; 30(19):3034-41. PubMed ID: 22008818
[TBL] [Abstract][Full Text] [Related]
15. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
16. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.
Brehm M; Samaniego LA; Bonneau RH; DeLuca NA; Tevethia SS
Virology; 1999 Apr; 256(2):258-69. PubMed ID: 10191191
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
Sin JI; Kim JJ; Zhang D; Weiner DB
Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
[TBL] [Abstract][Full Text] [Related]
20. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
